Proceedings from the First Onco Summit: LATAM Chapter, 19–20 May 2023, Rio de Janeiro, Brazil
Hungria V. et al, (2024), Cancers, 16
Challenges in designing and running smouldering myeloma interventional clinical trials.
Lecat C. et al, (2024), EJHaem, 5, 418 - 420
Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper.
Hughes D. et al, (2024), Br J Haematol
Longitudinal dynamics and clinically available predictors of poor response to COVID-19 vaccination in multiple myeloma.
Agarwal G. et al, (2024), Haematologica
INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice.
Leleu X. et al, (2024), Future Oncol
Determinants of durable humoral and T cell immunity in myeloma patients following COVID-19 vaccination.
Twumasi C. et al, (2023), Eur J Haematol
Multiple myeloma and its treatment contribute to increased platelet reactivity.
Mitchell JL. et al, (2023), Platelets, 34
Use Via Early Access to Ixazomib (UVEA-IXA) Study: Effectiveness and Safety of Ixazomib-based Therapy in Relapsed/Refractory Multiple Myeloma Outside of the Clinical Trial Setting.
Ludwig H. et al, (2023), Clin Lymphoma Myeloma Leuk
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.
Richardson PG. et al, (2023), N Engl J Med, 389, 1009 - 1022
Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study.
Ramasamy K. et al, (2023), Hemasphere, 7
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel.
Raje N. et al, (2023), Blood Cancer J, 13
P864: A PHASE 1 STUDY OF BELANTAMAB MAFODOTIN IN COMBINATION WITH STANDARD OF CARE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: AN INTERIM ANALYSIS OF DREAMM-9
Usmani SZ. et al, (2023), HemaSphere, 7
P945: REAL-WORLD CLINICAL OUTCOMES AMONG TRIPLE-CLASS EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS IN US AND EUROPE: A PREAMBLE REGISTRY STUDY
Ramasamy K. et al, (2023), HemaSphere, 7
P1362: DEVELOPMENT OF A NOVEL ONCOLYTIC VIRUS -THEO-310 - SPECIALISED FOR TARGETING THE BONE MARROW TUMOUR MICROENVIRONMENT OF MULTIPLE MYELOMA PATIENTS
Bamford R. et al, (2023), HemaSphere, 7
Léčba pacientů s mnohočetným myelomem po expozici lenalidomidu a postavení přípravku Ninlaro v terapeutické sekvenci
Ramasamy K., (2023), Onkologie (Czech Republic), 17, 209 - 214